Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Tracy, McGowan"'
Autor:
Robin L. Jones, Thomas J. Herzog, Shreyaskumar R. Patel, Margaret von Mehren, Scott M. Schuetze, Brian A. Van Tine, Robert L. Coleman, Roland Knoblauch, Spyros Triantos, Peter Hu, Waleed Shalaby, Tracy McGowan, Bradley J. Monk, George D. Demetri
Publikováno v:
Cancer Medicine, Vol 10, Iss 11, Pp 3565-3574 (2021)
Abstract Background As with other alkylating agents, cardiac dysfunction can occur with trabectedin therapy for advanced soft tissue sarcomas (STS) or recurrent ovarian cancer (ROC) where treatment options for advanced disease are still limited. Card
Externí odkaz:
https://doaj.org/article/f437f40c60df4df4949dc5750e11832b
Autor:
Bradley J. Monk, Thomas J. Herzog, George Wang, Spyros Triantos, Scott Maul, Roland Knoblauch, Tracy McGowan, Waleed S.W. Shalaby, Robert L. Coleman
Publikováno v:
Data in Brief, Vol 30, Iss , Pp 105465- (2020)
The data presented herein are supplementary to our published primary article “A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian canc
Externí odkaz:
https://doaj.org/article/3efa6e26300e47cfaf5c6b14c7d74dfb
Autor:
Gordon Brown, Laurence Belkoff, Jason M. Hafron, Daniel R. Saltzstein, Rushikesh Potdar, Amitabha Bhaumik, Jennifer Phillips, Tracy McGowan, Neal D. Shore
Publikováno v:
Targeted Oncology. 18:95-103
The single-arm, open-label, multicenter, phase II Apa-RP study evaluates the biochemical recurrence (confirmed prostate-specific antigen [PSA] 0.2 ng/mL)-free rate in patients with high-risk localized prostate cancer (HR-LPC) after radical prostatect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be2aa8415cb162a6313dc0696bc30198
https://doi.org/10.1007/s11523-022-00932-8
https://doi.org/10.1007/s11523-022-00932-8
Autor:
Shreyaskumar Patel, Tracy McGowan, Spyros Triantos, Margaret von Mehren, Scott M. Schuetze, Roland Elmar Knoblauch, Waleed Shalaby, Peter Hu, Brian A. Van Tine, Bradley J. Monk, Robert L. Coleman, Thomas J. Herzog, Robin L. Jones, George D. Demetri
Publikováno v:
Cancer Medicine, Vol 10, Iss 11, Pp 3565-3574 (2021)
Cancer Medicine
Cancer Medicine
Background As with other alkylating agents, cardiac dysfunction can occur with trabectedin therapy for advanced soft tissue sarcomas (STS) or recurrent ovarian cancer (ROC) where treatment options for advanced disease are still limited. Cardiac safet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7391d426cc44ae5b508c00b6d9fc2b18
https://doi.org/10.1002/cam4.3903
https://doi.org/10.1002/cam4.3903
Autor:
Waleed Shalaby, Scott Maul, Bradley J. Monk, Spyros Triantos, George Wang, Roland Elmar Knoblauch, Thomas J. Herzog, Robert L. Coleman, Tracy McGowan
Publikováno v:
Gynecologic Oncology. 156:535-544
Objective This phase 3 study aimed to compare overall survival (OS) of women with platinum-sensitive, recurrent ovarian cancer (ROC) treated with third-line trabectedin (T) + pegylated liposomal doxorubicin (PLD) vs. PLD monotherapy. Methods Women wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d41f00216a5105114429433c87eef24
https://doi.org/10.1016/j.ygyno.2019.12.043
https://doi.org/10.1016/j.ygyno.2019.12.043
Autor:
Shreyaskumar Patel, Robert G. Maki, Tracy McGowan, Robin L. Jones, George Wang, Roland Elmar Knoblauch, Waleed Shalaby, George D. Demetri, Margaret von Mehren
Publikováno v:
Cancer
Background The results of the randomized, phase 3 ET743‐SAR‐3007 trial demonstrated that trabectedin had a significantly longer progression‐free survival (PFS) compared with dacarbazine in patients with advanced leiomyosarcoma/liposarcoma after
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a8a7717942d765e32e631dc8f9567b4
http://europepmc.org/articles/PMC6916570
http://europepmc.org/articles/PMC6916570
Autor:
Lucille Ferrante, Radhakrishnan Ramchandren, Tracy McGowan, Andre Goy, Peter Martin, Anil Londhe, Nancy L. Bartlett
Publikováno v:
Journal of Oncology Pharmacy Practice. 25:1027-1030
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::107f31038afcd770c11b60952130e07e
https://doi.org/10.1177/1078155219831435
https://doi.org/10.1177/1078155219831435
Autor:
Jennifer Phillips, Charles J. Ryan, Tracy McGowan, Willie Underwood, Anil Londhe, E. David Crawford, Peter St. John Francis, Philip W. Kantoff, Neal D. Shore, Mary-Ellen Taplin
Publikováno v:
Journal of Urology. 200:344-352
PURPOSE: To evaluate the use of abiraterone acetate (1000 mg) plus prednisone (5mg) [AA+P] in patients with high-risk non-metastatic castration resistant prostate cancer (nmCRPC). MATERIALS AND METHODS: Patients considered at high risk for progressio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::946ff4c2febc4c3f1a8c3be549edef94
https://doi.org/10.1016/j.juro.2018.03.125
https://doi.org/10.1016/j.juro.2018.03.125
Autor:
Nonko Pelhivanov, Anil Londhe, Leonard G. Gomella, Mary B. Todd, Tracy McGowan, Robert Charnas, Karim Fizazi, Charles J. Ryan, Bruce Montgomery, Neal D. Shore, Kurt Miller, Dana E. Rathkopf, Kim N. Chi, Howard I. Scher, Peter De Porre, Johann S. de Bono
Publikováno v:
European Urology. 70:438-444
Background Abiraterone acetate (AA) is the prodrug of abiraterone, which inhibits CYP17A1 and testosterone synthesis and prolongs the survival of patients with metastatic castration-resistant prostate cancer (mCRPC). AA plus prednisone (P) (AA+P) is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::108d90fb595ff9dad5af86f154bcdfe6
https://doi.org/10.1016/j.eururo.2016.02.035
https://doi.org/10.1016/j.eururo.2016.02.035
Autor:
Robert L. Coleman, B. De Rivas Otero, Tracy McGowan, Bradley J. Monk, A. Tanovic, Thomas J. Herzog, J. Gomez
Publikováno v:
Annals of Oncology. 31:S625
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3d43d67c8c935be452a55eafadfe9faa
https://doi.org/10.1016/j.annonc.2020.08.969
https://doi.org/10.1016/j.annonc.2020.08.969